المؤلفون: Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: PARPi, combination therapy, homologous recombination, BRCA wild type, DNA single-strand breaks, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1441222/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/b534ae76c0a643389d517702734710d5

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Andrew K. Godwin, Dineo Khabele, Qi Chen, Ping Chen, Jeanne Drisko, Yan Ma

المصدر: Oncology Letters

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Veliparib, endocrine system diseases, DNA damage, Poly (ADP-Ribose) Polymerase Inhibitor, olaparib, Olaparib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, PARP inhibitors, Oncogene, BRCA wild-type, Chemistry, Articles, Cell cycle, ascorbate, medicine.disease, female genital diseases and pregnancy complications, 030104 developmental biology, ovarian cancer, Oncology, Apoptosis, 030220 oncology & carcinogenesis, Cancer research, Ovarian cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ce75f6524d7a41cff9016b216cbcb2
http://europepmc.org/articles/PMC7068513

المؤلفون: Andrés Redondo, M. Iglesias, E.M. Guerra, Ana Santaballa, L. Manso Sánchez, E. Calvo García, Ángel Fernández Cortés, Jose Alejandro Perez-Fidalgo, Y. García, Ana Oaknin, Antonio González-Martín, Mauricio Rubio, U. Bohn Sarmiento

المساهمون: Institut Català de la Salut, [Perez-Fidalgo JA] Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Cortés A, Guerra E] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [García Y] Department of Medical Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, Sabadell, Spain. [Iglesias M] Department of Medical Oncology, Hospital Son Llatzer, Palma De Mallorca, Spain. [Bohn Sarmiento U] Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas De Gran Canaria, Spain. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: ESMO Open
Esmo Open
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, Anemia, medicine.medical_treatment, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], platinum-resistant recurrent ovarian cancer, neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas [ENFERMEDADES], Neutropenia, Other subheadings::Other subheadings::/drug therapy [Other subheadings], olaparib, Quimioteràpia combinada, Disease-Free Survival, Piperazines, Olaparib, Polyethylene Glycols, chemistry.chemical_compound, pegylated liposomal doxorubicin, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Other subheadings::/therapeutic use [Other subheadings], Adverse effect, Original Research, Ovarian Neoplasms, Chemotherapy, BRCA wild-type, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms [DISEASES], terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Ovaris - Càncer - Tractament, medicine.disease, PARP inhibitor, chemistry, Doxorubicin, Avaluació de resultats (Assistència sanitària), Phthalazines, Female, Neoplasm Recurrence, Local, Ovarian cancer, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba58aff95f7fe79c4dcfa013db5de1f2
https://pubmed.ncbi.nlm.nih.gov/34329939

المؤلفون: Tristan M. Sissung, Lori M. Minasian, Victoria L. Chiou, William D. Figg, Elise C. Kohn, Nicole D. Houston, Christina M. Annunziata, Erika J. Lampert, John L. Hays, Minshu Yu, Jung-Min Lee, Nicolas Gordon

المصدر: Oncotarget

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Anemia, BRCA wild type, Neutropenia, olaparib, Olaparib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, high-grade serous ovarian cancer, Ovarian carcinoma, Internal medicine, medicine, Adverse effect, business.industry, medicine.disease, Carboplatin, Serous fluid, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, carboplatin, Toxicity, business, Research Paper

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8d4ccdb46e69b4cd64811d403d0d0b
https://doi.org/10.18632/oncotarget.26869

المؤلفون: Perez-Fidalgo, JA, Cortes, A, Guerra, E, Garcia, Y, Iglesias, M, Sarmiento, UB, Garcia, EC, Sanchez, LM, Santaballa, A, Oaknin, A, Redondo, A, Rubio, MJ, Gonzalez-Martin, A

المصدر: Esmo Open
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

مصطلحات موضوعية: PARP inhibitor, pegylated liposomal doxorubicin, endocrine system diseases, BRCA wild-type, platinum-resistant recurrent ovarian cancer, olaparib

URL الوصول: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f6cb62eef99dc78bb4ea4faec5946cfa
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14693

المؤلفون: Elizabeth M. Swisher, Min-Jung Lee, Mohammad Hadi Bagheri, Jung-Min Lee, Alexandra S Zimmer, Elise C. Kohn, Irene Ekwede, Dana-Adriana Botesteanu, Jane B. Trepel, Jayakumar R. Nair, Christina M. Annunziata, Maria J. Merino, Stanley Lipkowitz, Lori M. Minasian, Seth M. Steinberg, Maria I. Harrell

المصدر: The Lancet. Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Time Factors, cell cycle checkpoint kinase inhibitor, 0302 clinical medicine, Ovarian carcinoma, Medicine, Prexasertib, Ovarian Neoplasms, education.field_of_study, BRCA1 Protein, Middle Aged, Prognosis, Serous fluid, Treatment Outcome, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Pyrazines, Female, Adult, medicine.medical_specialty, Population, Neutropenia, Risk Assessment, Disease-Free Survival, Article, CCNE1 amplification and/or overexpression, 03 medical and health sciences, Young Adult, Internal medicine, high-grade serous ovarian cancer, Humans, Neoplasm Invasiveness, education, Aged, Neoplasm Staging, BRCA2 Protein, BRCA wild-type, business.industry, Cancer, Cell Cycle Checkpoints, medicine.disease, Survival Analysis, United States, Cystadenocarcinoma, Serous, 030104 developmental biology, Checkpoint Kinase 1, Pyrazoles, Neoplasm Recurrence, Local, business, Ovarian cancer, Febrile neutropenia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f212a0b881fde1330eaf391ad788b7
http://europepmc.org/articles/PMC7366122

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.